1-5 of 5
Yunfeng Li
Close
Sort by
Journal Articles

A Mediator Switch Tunes Transcription Pausing to Drive Erythropoiesis

Hsiang-Ying Lee, Shicong Zhu, Xiaoting Zhang, Man Li, Xinying Zhao, Na Li, Sera Xie, Qiuyu Yue, Yunfeng Li, Dong Li, Fan Wu, Zile Zhang, Ziqi Feng, Yuelin Deng, Qi Hu, Xingyun Yao, Xiaofei Gao
Journal: Blood
Blood (2023) 142 (Supplement 1): 10.
https://doi.org/10.1182/blood-2023-189195
Published: 2023
Journal Articles

Ibrutinib for chronic graft-versus-host disease after failure of prior therapy

Clinical Trials & Observations
David Miklos, Corey S. Cutler, Mukta Arora, Edmund K. Waller, Madan Jagasia, Iskra Pusic, Mary E. Flowers, Aaron C. Logan, Ryotaro Nakamura, Bruce R. Blazar, Yunfeng Li, Stephen Chang, Indu Lal, Jason Dubovsky, Danelle F. James, Lori Styles, Samantha Jaglowski
Journal: Blood
Blood (2017) 130 (21): 2243–2250.
https://doi.org/10.1182/blood-2017-07-793786
Published: 2017
Includes: Supplemental data
Journal Articles

Multicenter Open-Label Phase 2 Study of Ibrutinib in Chronic Graft Versus Host Disease (cGVHD) after Failure of Corticosteroids

David Miklos, MD, Corey S. Cutler, MD MPH, Mukta Arora, MD, Edmund K. Waller, MD PhD FACP, Madan Jagasia, MD MBBS, MS, Iskra Pusic, MD, Mary E. Flowers, MD, Aaron C. Logan, MD PhD, Ryotaro Nakamura, MD, Bruce R. Blazar, MD, Yunfeng Li, PhD, Indu Lal, MD, Jason Dubovsky, PhD, Danelle F. James, MD, Lori Styles, MD, Samantha Jaglowski, MD PhD
Journal: Blood
Blood (2016) 128 (22): LBA-3.
https://doi.org/10.1182/blood.V128.22.LBA-3.LBA-3
Published: 2016
Journal Articles

Outcome of Ibrutinib Treatment by Baseline Genetic Features in Patients with Relapsed or Refractory CLL/SLL with del17p in the Resonate-17 Study

Stephan Stilgenbauer, MD, Jeffrey A. Jones, MD MPH, Steven Coutre, MD, Anthony R. Mato, MD MSCE, Peter Hillmen, MB, ChB, PhD, Constantine Tam, MBBS, MD, Anders Osterborg, MD PhD, Tanya Siddiqi, MD, Michael J. Thirman, MD, Richard R. Furman, MD, Osman Ilhan, Michael Keating, MBBS, Timothy G. Call, MD, Jennifer R. Brown, MD PhD, Yunfeng Li, PhD, Karl Eckert, BA, Betty Y. Chang, PhD, Danelle F. James, MD MAS, Alvina D. Chu, MD, Michael Hallek, MD, Susan O'Brien, MD
Journal: Blood
Blood (2015) 126 (23): 833.
https://doi.org/10.1182/blood.V126.23.833.833
Published: 2015
Journal Articles

Efficacy and Safety of Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia with 17p Deletion: Results from the Phase II RESONATE™-17 Trial

Susan O'Brien, MD, Jeffrey A. Jones, MD, Steven Coutre, MD, Anthony R. Mato, MD, Peter Hillmen, MB, ChB, PhD, Constantine Tam, MD, Anders Osterborg, MD PhD, Tanya Siddiqi, MD, Michael J. Thirman, MD, Richard R. Furman, MD, Osman Ilhan, MD, Michael Keating, MBBS, Timothy G. Call, MD, Jennifer R. Brown, MD PhD, Michelle Stevens-Brogan, MS, Yunfeng Li, PhD, Maria Fardis, PhD MBA, Fong Clow, ScD, Danelle F. James, MD MAS, Alvina D. Chu, MD, Michael Hallek, MD, Stephan Stilgenbauer, MD
Journal: Blood
Blood (2014) 124 (21): 327.
https://doi.org/10.1182/blood.V124.21.327.327
Published: 2014